PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
2G Energy AG has secured a significant order from its Data Center business segment
2G Energy AG secures significant order in Data Center business segment, expecting group revenues at upper end of guidance for 2026 and sales growth in 2027. Order volume in low triple-digit megawatt range -
PRESS RELEASE
EQS-Adhoc: 2G Energy AG receives major order to supply power generation equipment to data centers in north America: 2026 revenue forecast confirmed at the upper end of the range; significant revenue growth of 20
2G Energy AG receives major order to supply power generation equipment to data centers in North America, confirming 2026 revenue forecast at upper end. Expecting 20% revenue growth in 2027 -
PRESS RELEASE
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.39 Million Tokens, and Total Crypto and Total Cash Holdings of $12.3 Billion
Bitmine Immersion Technologies announces 5.39 million ETH holdings and $12.3 billion total crypto and cash holdings. Company aims to acquire 5% of ETH. Uplisted to NYSE -
PRESS RELEASE
Klondike Gold Announces 2026 Diamond Drilling Program Underway to Update and Expand Gold Mineral Resources
Klondike Gold Corp. commences 2026 diamond drilling program at Klondike District Project in Yukon Territory. Program aims at expanding mineralization and updating gold resource estimate -
PRESS RELEASE
Predictiv AI Announces Strategic Healthcare Partnership and CloudRep AI Integration with Clinicmaster Following Successful Multi-Clinic Pilot Deployments
Predictiv AI partners with ADDATech Systems Inc. for healthcare integration. CloudRep AI offers AI-powered patient communication and workflow automation services for clinics in Canada -
PRESS RELEASE
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial -
